Abstract: The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist. Also provided are methods for the treatment of conditions associated with angiogenesis, comprising administering a multi-specific compound that targets a phosphatase and a receptor tyrosine kinase agonist.
Abstract: Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.
Type:
Grant
Filed:
February 27, 2017
Date of Patent:
January 12, 2021
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Jean X. Jiang, Zhiqiang An, Ningyan Zhang, Wei Xiong, Manuel A. Riquelme, Sumin Gu, Naomi Ledene Sayre
Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
Abstract: The present invention provides chimeric antigen receptor cells specific for carbonic anhydrase IX (CAIX) and methods of using same for treatment of CAIX expressing cancers such as renal cell carcinoma.
Abstract: This disclosure generally provides molecules that specifically engage glucocorticoid-induced TNFR-related protein (GITR), a member of the TNF receptor superfamily (TNFRSF). More specifically, the disclosure relates to multivalent and/or multispecific molecules that bind at least GITR.
Type:
Grant
Filed:
August 31, 2018
Date of Patent:
November 24, 2020
Assignee:
Inhibrx, Inc.
Inventors:
John C. Timmer, Kyle S. Jones, Amir Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
Abstract: This disclosure provides anti-CXCR5 antibodies and their use in the amelioration, treatment, or prevention of lupus. The disclosure also provides prophylactic, immunotherapeutic, and diagnostic compositions comprising an anti-CXCR5 antibody, and the use of such anti-CXCR5 antibodies in methods of preventing or treating lupus in mammals, including humans.
Type:
Grant
Filed:
March 21, 2018
Date of Patent:
November 24, 2020
Assignee:
Sanofi
Inventors:
Jeffrey Ming, Moshe E. Zilberstein, Roghieh Karimi Anderesi
Abstract: Disclosed herein are methods, platform, antibodies, vaccines, constructs, and kits for generating a modified multispanning membrane polypeptide. In some instances, also disclosed herein are methods, platform, antibodies, vaccines, constructs, and kits for generating a modified ion channel polypeptide. In some cases, further disclosed herein are methods, platform, antibodies, vaccines, constructs, and kits for generating a modified GPCR.
Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.
Abstract: The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.
Type:
Grant
Filed:
June 16, 2017
Date of Patent:
November 10, 2020
Assignees:
INSERM (INSTITUTE NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Université Toulouse III—Paul Sabatier, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Abstract: Compositions and methods for preventing, ameliorating or treating biofilm infections are provided, including biofilms comprising at least one Pseudomonad or Staphylococcus, such as S. aureus. The biofilm infections may be associated with artificial joints, prostheses or implants.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
November 3, 2020
Assignee:
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Abstract: Disclosed herein are chimeric antigen receptors (CARs) comprising an intracellular segment comprising an interleukin receptor chain, a JAK-binding motif, a Signal Transducer and Activator of Transcription (STAT) 5 association motif and/or a CD3? intracellular signaling domain comprising an exogenous STAT3 association motif, as well as cells and 5 compositions comprising said CARs and uses thereof.
Type:
Grant
Filed:
May 14, 2019
Date of Patent:
November 3, 2020
Assignees:
University Health Network, Takara Bio Inc.
Abstract: The invention relates to methods of treating chronic intestinal inflammation and/or inflammatory bowel disease by administering an antagonist of oncostatin-M (OSM) and/or OSM receptor-? (OSMR). The invention also relates to methods for diagnosing or prognosing chronic intestinal inflammation and/or inflammatory bowel disease in an individual and for predicting whether or not an individual will respond to an anti-TNF? therapy. The methods comprise measuring OSM and/or OSMR in the individual.
Type:
Grant
Filed:
January 28, 2016
Date of Patent:
November 3, 2020
Assignee:
Oxford University Innovation Limited
Inventors:
Nathaniel Richard West, Benjamin Michael Joseph Owens, Ahmed Nabil Hegazy, Fiona Margaret Powrie
Abstract: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
Type:
Grant
Filed:
April 3, 2019
Date of Patent:
October 20, 2020
Assignees:
BioNTech RNA Pharmaceuticals GmbH, Universität Stuttgart, TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GGMBH
Inventors:
Ugur Sahin, Friederike Gieseke, Ronald Backer, Sebastian Kreiter, Roland Kontermann, Klaus Pfizenmaier, Sina Fellermeier, Dafne Müller
Abstract: The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.
Type:
Grant
Filed:
August 19, 2016
Date of Patent:
October 13, 2020
Assignee:
AUTOLUS LIMITED
Inventors:
Martin Pulé, Shaun Cordoba, Matteo Righi, James Sillibourne, Shimobi Onuoha, Simon Thomas
Abstract: The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.
Type:
Grant
Filed:
August 27, 2018
Date of Patent:
October 13, 2020
Assignee:
AUTOLUS LIMITED
Inventors:
Martin Pulé, Shaun Cordoba, Matteo Righi, James Sillibourne, Shimobi Onuoha, Simon Thomas
Abstract: Disclosed herein are switchable chimeric receptors, switchable chimeric receptor effector cells and chimeric receptor effector cell switches. The switchable chimeric receptor-ECs are generally T cells. The chimeric receptors have non-antibody extracellular domains that recognize a chimeric receptor binding partner on the chimeric receptor-EC switch or target cell. The chimeric receptor-ECs and switches may be used for the treatment of a disease or condition in a subject in need thereof.
Type:
Grant
Filed:
March 28, 2016
Date of Patent:
October 13, 2020
Assignee:
THE SCRIPPS RESEARCH INSTITUTE
Inventors:
Travis Young, Chanhyuk Kim, Peter G. Schultz
Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
Type:
Grant
Filed:
April 19, 2019
Date of Patent:
September 29, 2020
Assignee:
Pieris Pharmaceuticals GmbH
Inventors:
Marlon Hinner, Andrea Allersdorfer, Rachida Siham Bel Aiba, Michaela Aloe, Alexander Wiedenmann, Gabriele Matschiner, Martin Huelsmeyer
Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.
Type:
Grant
Filed:
February 5, 2015
Date of Patent:
September 15, 2020
Assignees:
MEDIMMUNE, LLC, ABBOTT LABORATORIES
Inventors:
Partha S. Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker, Gerard Davis, Nicolette Jeanblanc, Susan Brophy, Bruce Dille